More than 25% of heart attack patients experience ongoing chest pain or heart failure in the year following successful interventions. The culprit is often microvascular obstruction (MVO), which occurs when small blood vessels become blocked, leading to the death of heart muscle. MVO can go undetected and untreated during the initial procedure, even though it’s the most powerful prognostic indicator for future adverse outcomes. For every 1% increase in MVO, there’s a corresponding 14% increase in one-year mortality risk and 8% increase in hospitalization due to heart failure.
CorFlow’s CoFI system was designed by interventional cardiologists to enable the rapid detection and treatment of MVO while patients are in the catheter laboratory, also offering the ability to safely deliver therapeutic agents directly into the microvasculature. CoFI seamlessly fits into standard workflows as well using existing guide catheter and wire access, minimizing the additional procedural time.
CorFlow’s CoFI system has earned the coveted U.S. Food and Drug Administration Breakthrough Designation for medical devices that provide more effective treatment of potentially life-threatening or irreversible conditions or diseases.
BioSpace – CorFlow Announces Positive Data from the MOCA I First-in-Human Study Presented at EuroPCR 2023
Cardiac Interventions Today – CorFlow’s CoFI System Evaluated in MOCA I First-in-Human Study for Detecting Microvascular Obstruction
Cardiac Interventions Today – CorFlow’s Controlled Flow Infusion System Granted FDA Breakthrough Device Designation
CardiovascularNews – FDA Grants Breakthrough Device Designation to CorFlow Infusion System
Diagnostic and Interventional Cardiology – CorFlow Presents New Insights into Coronary Microcirculation at ACC
Drug Delivery Business News – CorFlow Therapeutics Raises $48.5M for Diagnostic, Drug Delivery Platform
FinSMES – CorFlow Completes $9.7M Funding
FinSMES – CorFlow Therapeutics Raises €44M in Series B Funding
MassDevice – CorFlow Closes $3M Seed Round
MassDevice – FDA Grants Breakthrough Status to CorFlow’s CoFI Device
PCR Online – The CorFlow MOCA I Trial: Learnings from the First-in-Human Direct Measurement of Microvascular Obstruction in STEMI
Startup Ticker – CorFlow Receives the FDA Breakthrough Device Designation
Startup Ticker – CorFlow Reports Positive Interim Results of Phase 1 Clinical Trials
U.S. Food and Drug Administration – Breakthrough Device Designation
We invest in early-stage startups all around the world, often helping overseas companies open their first American offices. Click below to tell us about your work.
